Connect your AI

AbCellera Biologics Inc. ABCL Price / book

Price / book at other companies

Twist Bioscience CorporationTWST

6.4×+1.1×

Recursion Pharmaceuticals, Inc.RXRX

1.6×-0.7×

AnaptysBio, Inc.ANAB

125.1×+108×

PrecigenPGEN

67.7×—

ZymeworksZYME

11.4×+8.8×

ADMA BiologicsADMA

5.5×-7.1×

Other financials

Income statement

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

Market cap$1.72B+59.2%

Enterprise value$1.76B+100.0%

P/S21.7×-25.0×

Profitability

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Calculated from AbCellera Biologics Inc.’s reported figures.

market cap/total stockholders equity=1.1×

Based on the most recent quarter.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AbCellera Biologics Inc.'s price / book?: AbCellera Biologics Inc. (ABCL) reported price / book of 1.1× in Q1 2026.
How has AbCellera Biologics Inc.'s price / book changed year-over-year?: AbCellera Biologics Inc.'s price / book increased by 73.6% year-over-year, from 0.6× to 1.1×.
What is the long-term trend for AbCellera Biologics Inc.'s price / book?: Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s price / book has grown at a -40.0% compound annual growth rate (CAGR), from 13.6× to 1.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.